Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Sarepta Therapeutics's annualized net income for the quarter that ended in Mar. 2026 was MXN23,872 Mil. Sarepta Therapeutics's average shareholder tangible equity for the quarter that ended in Mar. 2026 was MXN23,296 Mil. Therefore, Sarepta Therapeutics's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 102.47%.
The historical rank and industry rank for Sarepta Therapeutics's Return-on-Tangible-Equity or its related term are showing as below:
MEX:SRPT'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -108.97 Med: -62.97 Max: 20.19
Current: 5.15
During the past 13 years, Sarepta Therapeutics's highest Return-on-Tangible-Equity was 20.19%. The lowest was -108.97%. And the median was -62.97%.
MEX:SRPT's Return-on-Tangible-Equity is ranked better than 82.15% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs MEX:SRPT: 5.15
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Sarepta Therapeutics Return-on-Tangible-Equity Related Terms
Sarepta Therapeutics Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Sarepta Therapeutics's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:SRPT vs ZYME, BCAX, INVA: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Sarepta Therapeutics's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sarepta Therapeutics Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Sarepta Therapeutics's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 102.47% mean?
Sarepta Therapeutics (MEX:SRPT) has a Return-on-Tangible-Equity of 102.47% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sarepta Therapeutics and its competitors. According to the industry distribution chart, Sarepta Therapeutics ranks #214 out of 1199 companies in the Biotechnology industry, placing it in the top 17.8%.
Is Sarepta Therapeutics' Return-on-Tangible-Equity too high?
Sarepta Therapeutics' current Return-on-Tangible-Equity is 102.47%. Based on the distribution chart, Sarepta Therapeutics ranks #214 out of 1199 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Sarepta Therapeutics has a GF Score™ of 36/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sarepta Therapeutics' Return-on-Tangible-Equity compare to ZYME and BCAX?
According to the Biotechnology industry distribution chart, Sarepta Therapeutics ranks #214 out of 1199 companies for Return-on-Tangible-Equity. This places Sarepta Therapeutics in the top 18% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Sarepta Therapeutics and its competitors. Sarepta Therapeutics's current Return-on-Tangible-Equity is 102.47%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sarepta Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Sarepta Therapeutics (MEX:SRPT) is currently considered Possible Value Trap. The stock's GF Value™ is MXN2,058.94, compared to a current price of MXN294.00 — trading 85.7% below its estimated fair value. The current Return-on-Tangible-Equity is 102.47%. Sarepta Therapeutics' overall GF Score™ is 36/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Sarepta Therapeutics (MEX:SRPT), the current Return-on-Tangible-Equity is 102.47% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sarepta Therapeutics (MEX:SRPT) Overvalued in 2026?
Based on GuruFocus' analysis, Sarepta Therapeutics stock appears to be undervalued.
The current stock price of MXN294.00 is trading 85.7% below its estimated GF Value™ of MXN2,058.94.
GuruFocus considers Sarepta Therapeutics to be Possible Value Trap.
Key valuation signals for MEX:SRPT:
Return-on-Tangible-Equity: 102.47%
GF Value™: MXN2,058.94 vs. price of MXN294.00 (85.7% below fair value)
No single metric tells the full story. See the MEX:SRPT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.
36GF Score
Get the complete analysis for MEX:SRPT
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:SRPT has been successfully added to your 
